Chinese biotech developing orelabrutinib, a BTK-inhibitor drug for blood cancers, plus a broader oncology/autoimmune pipeline.
Chinese biotech developing orelabrutinib, a BTK-inhibitor drug for blood cancers, plus a broader oncology/autoimmune pipeline.
Sells orelabrutinib mainly in China, where hospital access and patient affordability depend on the national reimbursement list, which trades a negotiated lower price for much wider coverage. Autoimmune and cancer trials are paid for from sales, licensing deals and investor money. The company also has a Hong Kong listing alongside this Shanghai STAR Market line.
In one line: A Chinese BeiGene/Innovent, focused on BTK inhibitors.
Moat: narrow (IP / patents, regulatory licence). Patent-protected, approved domestic BTK-inhibitor competing with imported drugs like ibrutinib.
Headquarters: Beijing, China · Founded: 2015 · Employees: 1,259
Size InnoCare Pharma (688428.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.07B, the 1134th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥23.31 on 18 Nov 2026.
Performance Over six months the shares fell 7.4%, against +2.8% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 135.4% over the last twelve months (peer median +8.7%); the operating margin is 35.4% (peer median 14.7%).
Valuation It trades at 85.7× forward earnings against a peer median of 20.3× (most expensive of 17).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +344%, so the hurdle is -355 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 19.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.36B | CN¥2.36B | CN¥999M | CN¥733M | CN¥621M |
| Revenue growth | — | +136% | +36% | +18% | — |
| Gross profit | CN¥3.12B | CN¥2.07B | CN¥763M | CN¥517M | CN¥407M |
| EBITDA | n/a | CN¥571M | -CN¥438M | -CN¥609M | -CN¥709M |
| Net income | CN¥1.36B | CN¥642M | -CN¥441M | -CN¥631M | -CN¥887M |
| Free cash flow | CN¥364M | CN¥134M | -CN¥310M | -CN¥801M | -CN¥763M |
| Capital expenditure | CN¥132M | CN¥70.2M | CN¥78.2M | CN¥255M | CN¥370M |
| Total debt | CN¥2.13B | CN¥1.61B | CN¥1.57B | CN¥1.65B | CN¥343M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| InnoCare Pharma 688428.SS | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% |
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688428.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.8% | +2.2% | 3rd lowest of 21 |
| 6-month return | -7.4% | +2.8% | 8th lowest of 21 |
| Distance from 52-week high | -33.4% | -23.5% | 5th lowest of 21 |
| Revenue growth (TTM) | +135.4% | +8.7% | highest of 20 |
| Operating margin | 35.4% | 14.7% | 2nd highest of 19 |
| Forward P/E | 85.7× | 20.3× | most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | -10.9% | 1.5% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +344.2% | +8.5% | highest of 15 |
| Hurdle (Req g minus delivered) | -355.1 pp | -4.7 pp | least demanding of 15 |
| ROIC minus cost of capital | +19.9 pp | -0.5 pp | 4th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |